A Agilent Technologies Inc.

Agilent Technologies Announces Revolutionary Triple Quadrupole Mass Spectrometer

Agilent Technologies Inc. (NYSE:A) today, introduced the newest member of its family of triple quadrupole liquid chromatography mass spectrometers (triple quad LC/MS) at the American Society for Mass Spectrometry Conference (ASMS), being held June 3 through June 8 in Indianapolis, Indiana. The Ultivo triple quad is a transformative approach to LC/MS that integrates several hardware and software innovations designed to deliver even more improved business results for customers.

Ultivo is optimized to address the food and environmental routine testing segments employing triple quad LC/MS systems for quantitative analyses. Ultivo delivers robust performance, superior uptime, and easier serviceability, in a footprint that is 70% smaller than previous instruments. Customers can now significantly increase their analytical throughput without having to increase the size of their existing laboratories.

“We are a production lab experiencing some significant growth, so the ability to place more instrumentation in the same footprint in the lab is important,” said Johnny Mitchell, president at ESC Lab Sciences in Nashville, TN. “Without that ability we would be faced with some expensive construction costs to increase the size of our facilities.”

In addition to its trendsetting size, Ultivo provides reproducible, reliable assays that result in exceptional performance in complex matrices. Greater ion transmission efficiency leads to optimized sensitivity; and improved, intelligent diagnostics use intuitive readbacks that can quickly identify issues, ensuring optimum uptime. Furthermore, Ultivo’s new VacShield vacuum provides vent-less ion injector exchange capabilities that reduce wear and tear and facilitate rapid front-end maintenance.

“Agilent prides itself on actively listening to customers, and addressing their needs through the continuous development of innovative technology solutions. Ultivo provides a revolutionary new ‘fit for purpose’ triple quad LC/MS, that is smaller than could’ve been imagined, yet delivers the superior performance usually associated with much larger instruments,” said Monty Benefiel, vice president and general manager of Agilent’s Mass Spectrometry Division. “We are excited by our customers’ reactions so far, and expect that Ultivo will dramatically change the LC/MS landscape now, and for years to come.”

The food and environmental segments are important markets for Agilent. Ultivo’s seamless integration with the Agilent MassHunter Software suite provides high-performance instrument monitoring, data acquisition, analysis, and reporting for currently regulated and emerging environmental contaminants and pollutants in our water supplies. Also, Ultivo’s fine-tuning ensures rigorous accuracy, with selectivity, sensitivity, and precision monitoring, to deliver specific identification and quantitation of a wide range of contaminants, helping keep our worldwide food supplies safe.

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A), is a global leader in analytical laboratory technologies. With more than 50 years of insight and innovation, our instruments, software, services, solutions and people provide trusted answers to our customers’ most challenging questions. The company generated revenues of $4.20 billion in fiscal 2016 and employs about 13,000 people worldwide. Information about Agilent is available at www.agilent.com.

NOTE: Agilent Ultivo product web pages and associated content will all be available on www.agilent.com at 12:01AM June 6, 2017

EN
05/06/2017

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Agilent Technologies Inc.

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

 PRESS RELEASE

Agilent xCELLigence RTCA Instrumentation Applied in Recent FDA Approva...

SANTA CLARA, Calif.--(BUSINESS WIRE)-- (NYSE: A) is pleased to announce its role in supporting Autolus Therapeutics’ , a recently approved CAR T therapy. Agilent's advanced cell analysis instrumentation, specifically the technology, was applied in developing and validating AUCATZYL. The xCELLigence RTCA technology supported the development and implementation of the potency assay. By providing precise and reliable cell analysis solutions, Agilent assisted Autolus in achieving the high standards required for FDA approval. Dr. Xiaobo Wang, Vice President and General Manager of the Cell Functio...

 PRESS RELEASE

CORRECTING and REPLACING Agilent to Showcase Next-Generation Digital P...

SANTA CLARA, Calif.--(BUSINESS WIRE)-- Please replace the release with the following corrected version due to multiple revisions to the fifth paragraph. The updated release reads: AGILENT TO SHOWCASE NEXT-GENERATION DIGITAL PATHOLOGY SOLUTIONS AT USCAP 2025 (NYSE: A) is excited to announce its participation at the upcoming , which will be held March 22-27, 2025, in Boston. At the conference, Agilent will highlight innovative digital pathology solutions designed to enhance diagnostic accuracy and efficiency. In pathology, Agilent offers comprehensive tissue diagnostic solutions for analyzi...

 PRESS RELEASE

Agilent Research Catalyst Award Presented to Columbia University for P...

SANTA CLARA, Calif.--(BUSINESS WIRE)-- (NYSE: A) today announced that has received an Agilent Research Catalyst (ARC) Award on behalf of , an internationally recognized researcher and physician-scientist specializing in bone marrow transplant (BMT) and cancer cellular immunotherapy. Dr. Muranski is the Director of Cellular Immunotherapy Laboratory at Columbia University Irving Medical Center. He is also an Assistant Professor of Medicine at Columbia University Medical Center, a principal investigator at the Columbia Center for Translational Immunology (CCTI), and a member of the Herbert Irv...

 PRESS RELEASE

Agilent PD-L1 IHC 28-8 pharmDx Receives EU IVDR Certification as a Com...

SANTA CLARA, Calif.--(BUSINESS WIRE)-- (NYSE: A) today announced its kit has received two new companion diagnostic indications approvals under EU IVDR1, expanding the eligibility of treatment to early-stage non-small cell lung cancer (NSCLC) and previously untreated advanced melanoma patients. These two new indications bring the total indications launched in Europe for PD-L1 IHC 28-8 pharmDx to nine. PD-L1 IHC 28-8 pharmDx is approved for exclusive use with the advanced staining solution. Lung cancer and malignant melanoma are major healthcare concerns worldwide, with lung cancer accountin...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch